Investment
Features
FeesSafety
Academy
More
Pluang+

John Hancock HTD fund holds 7.5% yield but faces limited upside amid rate and regulatory risks.

Analyst Insights
11 Aug 2026
Seeking Alpha
View Source
Neutral
pluang ai news

The John Hancock Tax-Advantaged Dividend Income Fund (HTD) offers a 7.5% yield through a leveraged portfolio of utilities, financials, preferred stocks, and corporate bonds. While AI-driven electricity demand supports its utility holdings, high valuations and regulatory limits cap potential gains. The fund's leverage increases both returns and risks, making it vulnerable to rising interest rates or weak utility earnings that could pressure its net asset value and distributions. Given these factors, HTD is rated Hold due to limited upside and a narrowing discount to its net asset value.

More News

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is set to report quarterly earnings with an expected loss of $0.09 per share and revenue of $1.33 million, reflecting ongoing financial challenges. Despite negative profitability and cash flow metrics, the company received positiv...

Company Fundamentals
Neutral
1 hour ago
Applied Materials stock dips post-earnings despite strong results and raised price target to $700.

Applied Materials stock dips post-earnings despite strong results and raised price target to $700.

Applied Materials reported strong Q3 financial results with revenue up 25% to $9.12 billion and adjusted EPS rising 41% to $3.50, beating Wall Street estimates. However, the stock fell over 5% after earnings due to market expectations being even high...

Analyst Insights
Bullish
2 hours ago
Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital.

Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital.

Ascendis Pharma reported robust Q2 2026 results with total revenue of €339 million, driven by strong sales of its three main products: YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved a net profit of €207 million and ended the quarter with a...

Analyst Insights
Bullish
2 hours ago
Matador Resources posts record Q2 output, strong earnings, and CEO buys shares signaling confidence

Matador Resources posts record Q2 output, strong earnings, and CEO buys shares signaling confidence

Matador Resources reported a record oil production of 126,106 barrels per day in Q2 2026, driving a 70.6% rise in adjusted earnings per share to $2.61 and a 32.5% increase in revenues to $1.2 billion. The CEO's recent purchase of 5,000 shares at $51....

Company Fundamentals
Bullish
2 hours ago
Star Equity misses Q2 earnings and revenue targets despite 54.6% sales growth, net loss widens.

Star Equity misses Q2 earnings and revenue targets despite 54.6% sales growth, net loss widens.

Star Equity Holdings reported Q2 2026 results missing analyst expectations with an EPS of -$0.15 versus -$0.07 expected and revenue of $54.9 million below the $56.92 million forecast. Despite the miss, revenue grew 54.6% year-over-year, showing stron...

Company Fundamentals
Bearish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App